443 related articles for article (PubMed ID: 37888583)
1. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
2. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
3. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
4. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
8. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
9. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of Cholangiocarcinoma Immune Biology.
Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C
Cells; 2023 Mar; 12(6):. PubMed ID: 36980187
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in cholangiocarcinoma.
Al-Rajabi R; Sun W
Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
Liu J; Shu J
Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
Vatankhah F; Salimi N; Khalaji A; Baradaran B
Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
[TBL] [Abstract][Full Text] [Related]
15. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
Raggi C; Invernizzi P; Andersen JB
J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
[TBL] [Abstract][Full Text] [Related]
16. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
Wang J; Loeuillard E; Gores GJ; Ilyas SI
Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
Minini M; Fouassier L
Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
[TBL] [Abstract][Full Text] [Related]
18. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
19. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies.
Yu X; Zhu L; Wang T; Chen J
Front Immunol; 2023; 14():1037945. PubMed ID: 37138880
[TBL] [Abstract][Full Text] [Related]
20. Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
Zimmer CL; Filipovic I; Cornillet M; O'Rourke CJ; Berglin L; Jansson H; Sun D; Strauss O; Hertwig L; Johansson H; von Seth E; Sparrelid E; Dias J; Glaumann H; Melum E; Ellis EC; Sandberg JK; Andersen JB; Bergquist A; Björkström NK
Hepatology; 2022 May; 75(5):1154-1168. PubMed ID: 34719787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
